Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2067-2077

  Xiao, Jing ^a   Leung, Joseph C K ^a   Chan, Loretta Y Y ^a   Guo, Hong ^a   Lai, Kar Neng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiotensin II type 1 receptor; IgA nephropathy; PPAR gamma agonist; Tubular epithelial cells; Tubulointerstitial injury

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 2 RECEPTOR; IMMUNOGLOBULIN A; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TROGLITAZONE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN A NEPHROPATHY; INTERSTITIAL NEPHRITIS; KIDNEY PROXIMAL TUBULE; MESANGIUM CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELLS, CULTURED; CHROMANS; EPITHELIAL CELLS; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; INFLAMMATION; KIDNEY TUBULES, PROXIMAL; MALE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 67649979340     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn746     Document Type: Article

References (38)

1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-748
2. Barratt J, Smith AC, Molyneux K et al. Immunopathogenesis of IgAN. Semin Immunopathol 2007; 29: 427-443
3. Daniel L, Saingra Y, Giorgi R et al. Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis 2000; 35: 13-20
4. Lai KN, Tang SC, Guh JY et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the reninangiotensin system. J Am Soc Nephrol 2003; 14: 3127-3137
5. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int 2006; 69: 1939-1944
6. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688
7. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70: 1223-1233
8. Sugawara A, Takeuchi K, Uruno A et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 2001; 142: 3125-3134
9. Takeda K, Ichiki T, Tokunou T et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000; 102: 1834-1839
10. Leung JC, Chan LY, Tang SC et al. Glycosylation profile of differently charge IgA1 and their binding characteristics to cultured mesangial cells in IgA nephropathy. Nephron 2007; 107: e107-e118
11. Chan LY, Leung JC, Tsang AW et al. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 2005; 67: 602-612
12. Chan WL, Leung JC, Chan LY et al. BMP-7 protects mesangial cells from injury by polymeric IgA. Kidney Int 2008; 74: 1026-1039
13. Lai KN, Leung JC, Chan LY et al. Activation of podocytes by mesangial-derived TNF-: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008; 294: F945-F955
14. Ballardie FW. Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol 2007; 18: 2806-2809
15. Xiong Z, Huang H, Li J et al. Anti-inflammatory effect of PPARgamma in cultured human mesangial cells. Ren Fail 2004; 26: 497-505
16. Tsuchiya T, Shimizu H, Shimomura K et al. Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am J Nephrol 2003; 23: 222-228
17. Maeda A, Horikoshi S, Gohda T et al. Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma. Cell Biol Int 2005; 29: 422-428
18. Routh RE, Johnson JH, McCarthy KJ. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 2002; 61: 1365-1376
19. Panchapakesan U, Sumual S, Pollock CA et al. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 2005; 289: F1153-F1158
20. Sommer M, Wolf G. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide. Am J Nephrol 2007; 27: 425-434
21. Tang SC, Leung JC, Chan LY et al. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. J Am Soc Nephrol 2006; 17: 1633-1643
22. Zafiriou S, Stanners SR, Polhill TS et al. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int 2004; 65: 1647-1653
23. Ko GJ, Kang YS, Han SY et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008; 23: 2750-2760
24. Ma LJ, Marcantoni C, Linton MF et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against non-diabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910
25. Miyazaki Y, Cersosimo E, Triplitt C et al. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007; 72: 1367-1373
26. Kincaid-Smith P, Fairley KF, Farish S et al. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 2008; 13: 58-62
27. Sato K, Sugawara A, Kudo M et al. Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertens Res 2004; 27: 417-425
28. Guan Y, Zhang Y, Davis L et al. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273: F1013-F1022
29. Elbrecht A, Chen Y, Cullinan CA et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 1996; 224: 431-437
30. Zanchi A, Perregaux C, Maillard M et al. The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats. Am J Physiol Endocrinol Metab 2006; 291: E1228-E1234
31. Imayama I, Ichiki T, Inanaga K et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 2006; 72: 184-190
32. Ricote M, Li AC, Willson TM et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82
33. Cowling RT, Gurantz D, Peng J et al. Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta. JBiolChem 2002; 277: 5719-5724
34. Liu D, Gao L, Roy SK et al. Neuronal angiotensin II type 1 receptor upregulation in heart failure: activation of activator protein 1 and Jun N-terminal kinase. Circ Res 2006; 99: 1004-1011
35. Berk BC. Angiotensin type 2 receptor (AT2R): a challenging twin. Sci STKE 2003; 2003: PE16
36. Leung JC, Tang SC, Chan LY et al. Synthesis of TNF-alpha by mesangial cells cultured with polymeric anionic IgA role of MAPK and NF-kappa B. Nephrol Dial Transplant 2008; 23: 72-81
37. Jung Y, Song S, Choi C. Peroxisome proliferator activated receptor gamma agonists suppress TNFalpha-induced ICAM-1 expression by endothelial cells in a manner potentially dependent on inhibition of reactive oxygen species. Immunol Lett 2008; 117: 63-69
38. Chawla A, Barak Y, Nagy L et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48-52